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Introduction
In Asia, there are still many men with prostate cancer who
present with locally advanced and/or metastatic disease at the
time of initial diagnosis. The prognosis then becomes dismal
in spite of treatment and such men suffer excess morbidity.
The mean survival of 3–3.5 years is a pale contrast to the figure
of 74–93% 10-year cancer-specific survival for those whose
cancer was organ-confined.1 Serum prostate specific antigen
(PSA) levels have been studied extensively; low levels indicate
a prognostically more favourable situation due to localized
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tumour, whereas a high level signals a generalized disease with
a short life expectancy.1 The association between PSA level and
tumour spread and symptoms is an important but not yet fully
answered question. We propose that patients’ initial serum
PSA level at presentation can reflect disease load, manifesting
as various morbid complications. There is currently no study
that reviews the correlation between serum PSA levels and
tumour-associated morbidity. In this study, we aim to review
the pattern of initial clinical manifestation of patients who
present with biochemically-advanced prostate carcinoma and
their median survival.
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OBJECTIVE: To review the pattern of initial clinical manifestation of patients who present with biochemically-
advanced prostate carcinoma.
METHODS: A review of 39 prostate cancer patients with initial prostate specific antigen (PSA) levels of more than
400 ng/mL (study group) and 40 patients whose initial PSA levels were between 20 and 399 ng/mL (control group)
was done.
RESULTS: The epidemiological profile and median Gleason score were similar in both groups. In the study and
control groups, the median initial PSA levels were 1,000 ng/mL (range, 400–20,000 ng/mL) and 83 ng/mL (range,
21.8–337 ng/mL) respectively. Patients in the study group had statistically significantly higher incidences of bone
pain, weight loss, loss of appetite, weakness in the lower limbs, and findings of abnormal prostate on digital rectal
examination than patients in the control group. Significantly higher morbidity, including spinal cord compression,
systemic lymphadenopathy, chronic urinary retention, elevated serum creatinine levels, anaemia and bone
metastases, were also seen in the study group compared to the control group. Similar proportions of patients in
the two groups developed hormone escape after treatment (50% in the study group, 45% in the control group). The
cancer-specific mortality rate was 39.5% in the study group and 17.5% in the control group.
CONCLUSION: There is a high incidence of excess morbidity in patients who present with biochemically-
advanced prostate carcinoma. [Asian J Surg 2005;28(3):202–6]
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Patients and methods
A review of the case records in our institution’s oncology
database of patients with prostate carcinoma between 1988
and 2003 was conducted. Based on these records, patients who
had histologically confirmed carcinoma of the prostate and
who were diagnosed as having locally advanced or metastatic
cancer and a very high initial serum PSA level at the time of
first presentation were selected for more detailed review. An
arbitrary cut-off serum PSA level of 400 ng/mL or more was
used to reflect a hundred-fold increase over the upper limit of
4 ng/mL. Records that had incomplete data or patients who
had no histological confirmation were excluded.
A total of 39 cases satisfied the above criteria. Records for
another 40 patients with PSA levels between 20 ng/mL and
399 ng/mL were also reviewed for comparison. All analyses
were performed using the SPSS statistical package (SPSS
Inc, Chicago, IL, USA); data are reported as mean or median,
and ranges. Chi-squared and Fisher’s exact tests were used for
categorical variables, Spearman’s correlation was used for
quantitative variable determination, and the Mann-Whitney
U test was used to determine differences in the means of
quantitative variables.
Results
The mean presenting age of the patients with PSA 400 ng/mL
or more (study group) was 70 years (range, 52–86 years), and
the percentages of ethnic Chinese, Malays, Indians and Cauca-
sians were 76.3%, 15.8%, 2.6% and 5.3%, respectively. For pa-
tients with PSA 20–399 ng/mL (control group), the epidemio-
logical profile was similar: the mean presenting age was 72
years (range, 53–87 years) and the percentages of ethnic Chinese,
Malays and Caucasians were 82.5%, 15.0% and 2.5%, respectively.
None of the patients reviewed had a history of prostate carci-
noma in their immediate families. The median initial serum
PSA level for the study and control groups were 1,000 ng/mL
(range, 400–20,000 ng/mL) and 83 ng/mL (range, 21.8–337
ng/mL) respectively. The median Gleason scores for the study
and control groups were 8 (range, 3–10) and 7 (range, 2–10),
respectively (Table). Histological diagnosis was obtained us-
ing transrectal ultrasound-guided biopsy of the prostate (study
group, 52.6%; control group, 65%), histology of prostatic chips
obtained from transurethral resection of the prostate (TURP)
(study group, 31.6%; control group, 32.5%), bone biopsies of
metastases (study group, 5.3%; control group, 2.5%) or core
biopsies of systemic lymph nodes (study group, 10.5%). Corre-
lation between PSA levels and Gleason grade scores, using
Spearman’s correlation, was significant for the control group
(r = 0.348, p < 0.05 [2-tailed]), but the correlation was not
significant for the study group.
Common presenting symptoms in both groups, in de-
scending order of frequency, are detailed in Figure 1; 65.8% of
patients in the study group and 27.5% of patients in the
control group had more than one presenting symptom. Com-
parisons made using the Chi-squared test revealed that pa-
tients in the study group were significantly more likely to
present initially with bone pain (p = 0.004; odds ratio [OR],
4.9; 95% confidence interval [CI], 1.6–15.1), loss of weight and
appetite (p = 0.014; OR, 10.1; 95% CI, 1.2–83.3) and weakness
in the lower limbs (p = 0.002; relative risk [RR], 1.26; 95% CI,
1.07–1.47) compared to those in the control group.
The physical findings at presentation of patients in both
groups are shown in Figure 2. Patients in the study group were
Table. Biological features, hormone escape characteristics and mortality data for patients with biochemically-advanced prostate
cancer (n = 79)
Control group (n = 40) Study group (n = 39)
Initial serum PSA, 20–399 ng/mL Initial serum PSA, * 400 ng/mL
Mean presenting age, yr 72 (range, 53–87) 70 (range, 52–86)
Median initial serum PSA, ng/mL 83 (range, 21.8–337) 1,000 (range, 400–20,000)
Median Gleason score 7 (range, 2–10) 8 (range, 3–10)
Hormone escape, % 45 50
Mean time to hormone escape, mo 7.5 (range, 3–60) 12 (range, 2–102)
Overall mortality rate, % 45 50
Mean time to overall mortality, mo 41.9 (range, 12–132) 81 (range, 1–972)
Cancer-specific mortality rate, % 17.5 39.5
PSA = prostate specific antigen.
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more likely to have suspicious findings from digital rectal
examination of the prostate (p = 0.033; OR, 27.0; 95% CI, 1.1–
6.6), palpable systemic lymphadenopathy (p = 0.029; OR,
8.5; 95% CI, 1.01–71.4), paraplegia (p = 0.002; RR, 1.26; 95% CI,
1.07–1.47) and a palpable bladder, reflecting chronic urinary
retention (p = 0.005; 95% CI, 1.05–1.41) compared to those in
the control group. All patients in the study group and only one
patient in the control group who had clinically palpable gen-
eralized lymphadenopathy (axillary, cervical or inguinal nodes)
also had enlarged intra-abdominal or intrathoracic lymph
nodes seen on computed tomography (CT) or magnetic reso-
nance imaging (MRI). Eight patients in the study group pre-
sented with paraplegia, whereas none did in the control group,
but this was not statistically significant.
At presentation, 10 (25.6%) patients in the study group and
three (7.5%) in the control group had elevated serum creati-
nine levels; this difference was statistically significant (p = 0.03;
OR, 4.3; 95% CI, 1.1–16.9). Of the patients in the study group
who had elevated serum creatinine levels, only 50% were re-
lated to renal hydronephrosis, while 66.7% of those who had
renal hydronephrosis had elevated serum creatinine levels.
Patients in the study group were significantly more likely to
present with anaemia (haemoglobin level < 11 g/dL) compared
to those in the control group (p = 0.008; OR, 5.5; 95% CI, 1.4–
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Figure 1. Common presenting symptoms of patients with biochemically-advanced prostate cancer. Comparisons between control and
study groups were made with the Chi-squared test (n = 79). *Statistically significant at p < 0.05. LUTS = lower urinary tract symptoms;
AUR = acute urinary retention; LOW/LOA = loss of weight/loss of appetite; NOS = not otherwise specified.
Figure 2. Common initial physical findings in patients with biochemically-advanced prostate cancer (n = 79). Comparisons between control
and study groups were made with the Chi-squared test (n = 79). *Statistically significant at p < 0.05. DRE = digital rectal examination;
LN = lymphadenopathy; RU = retention of urine.
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21.3). Bone metastases diagnosed via bone scans were also
more common in the study group compared to the control
group (p < 0.001). Eight patients in the study group who had
back pain and weakness in the lower limbs were found to have
spinal cord compression on MRI, while there was no incidence
of cord compression in the control group; this difference was
significant (p = 0.002; RR, 1.26; 95% CI, 1.07–1.47). The differ-
ence between the two groups in significant coagulopathy,
reflected by abnormal clotting profile and/or decreased serum
platelet counts, bacteriuria, hydronephrosis and incidence of
enlarged intra-abdominal or intrathoracic lymph nodes on
CT or MRI scans were not significantly different (Figure 3). All
patients in the study group who had clinically palpable gener-
alized lymphadenopathy (axillary, cervical or inguinal nodes)
also had enlarged intra-abdominal or intrathoracic lymph
nodes seen on CT or MRI scans. This was the case for only one
patient in the control group.
Anti-androgen medical therapy was the initial treatment
for 47.4% of study group patients and 47.5% of control group
patients; the remaining patients were treated with surgical
castration. Palliative radiotherapy to bone metastases was
administered to 47.4% and 5% of study and control group pa-
tients, respectively. Prostate radiotherapy was administered
to 12.5% of control group patients. In the study group, two pa-
tients had bilateral percutaneous nephrostomy drainage and
antegrade double-J ureteric stents inserted to relieve upper
tract obstruction. Fifty percent of patients in the study group
and 45% of patients in the control group developed hormone
escape (p = 0.58). Mean time to hormone escape for study and
control group patients were 12 months (range, 2–102 months)
and 7.5 months (range, 3–60 months) after initial hormone
treatment, respectively (p = 0.191). The mortality rate in the
study group was 57.9% after a mean of 81 months (range,
1–972 months), while the cancer-specific mortality rate was
39.5%. The mortality rate in the control group was 20% after
a mean of 41.9 months (range, 12–132 months), while the
cancer-specific mortality rate was 17.5% (Table). There were
no statistical differences in survival parameters between
the two groups (Mann-Whitney U test, p = 0.26).
Discussion
In patients with advanced prostate cancer, data in the litera-
ture indicate a mean survival of 3–3.5 years, and patients with
minimal metastatic load having an expected survival of 4–6
years.1 Endocrine treatment is still currently regarded as
palliative, and it is controversial as to whether endocrine
therapy can prolong survival.1 Serum PSA has been shown to
be a sensitive and, currently, the most useful marker for pros-
tate cancer in terms of detection, staging and monitoring
response to therapy.1–6 Serum PSA levels have also been shown
to correlate directly with advancing clinical and pathological
stage of prostate cancer,3,7–10 although PSA level alone may
not provide for accurate staging due to the overlap in PSA
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Figure 3. Investigative laboratory and imaging findings in patients with biochemically-advanced prostate cancer (n = 79). Comparisons
between control and study groups were made with the Chi-squared test (n = 79). *Statistically significant at p < 0.05. MRI = magnetic
resonance imaging; CT = computed tomography; Hb = haemoglobin.
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levels between stages.2 It has been shown that a serum PSA
level of less than 10 ng/mL indicates a higher likelihood of
organ-confined cancer, and more than 50% of men with PSA
levels above 10 ng/mL have extraprostatic disease.10,11 This
report aimed to outline the incidences of the various morbidities
of advanced prostate carcinoma so that clinicians can be more
aware of the common complications and problems in patients
with biochemically-advanced prostate carcinoma.
In our group of prostate cancer patients presenting ini-
tially with very high serum PSA levels (> 400 ng/mL), we found
that more than half had multiple symptoms at presentation,
while this was so in only one-quarter of the control group pa-
tients (PSA between 20 and 399 ng/mL). Local prostatic symp-
toms of lower urinary tract symptoms, acute urinary retention
and haematuria were common in both study and control
group patients. In the study group, bone pain, weakness in the
lower limbs, weight loss, and loss of appetite were present at
significantly higher rates than in the control group, reflecting
the manifestation of disease burden not just at the prostate
but also at the systemic level. Comparing physical findings
and investigation results at initial presentation for both groups
of patients also revealed a similar observation of study group
patients having more systemic manifestations than control
group patients. An interesting observation was that about
one-third of our study group patients had clinically palpable
systemic lymphadenopathy, and this correlated with a high
incidence of intracavity (intra-abdominal or pelvic) lymph
node enlargement as well. This observation was, however, not
so well seen in the control group. The incidences of renal im-
pairment and anaemia were significantly higher in the study
group than in the control group, while bilateral hydronephrosis,
coagulation abnormalities and systemic lymphadenopathy
were also present in a fairly high percentage of study group
patients. In patients with very high initial serum PSA levels
(study group), we also observed that bone metastases occurred
in 78.9% of patients, and the incidence of spinal cord compres-
sion was 20.5%. Patients with lower initial serum PSA levels
(control group) had a significantly much lower percentage of
bone metastases, with none of them having cord compression.
Aside from hormone treatment, radiotherapy to bone
metastases and channel TURP were the most common pallia-
tive therapies instituted for both groups of patients. The
indications for TURP were mainly to help wean patients off
urinary catheters for significant urine retention, to alleviate
symptoms of haematuria, and to relieve upper tract obstruction.
Percutaneous nephrostomies for hydronephroses or spinal
cord decompression were not performed for all affected pa-
tients as these patients were deemed to be terminally ill with
a poor prognosis. The prostate cancer-specific mortality rate
was 39.5% in the study group, which was similar to reported
literature;12 it was lower at 17.5% in the control group.
In conclusion, this report highlighted a high incidence of
morbidity, especially systemic manifestations of cancer, in
patients with biochemically-advanced prostate carcinoma who
present with very high initial serum PSA levels of 400 ng/mL
or more, compared to those with lower initial serum PSA
levels. The various incidence figures should prove to be useful
in increasing awareness of the excess morbidity that these
patients might suffer from.
References
1. Ekman P, Adolfsson J, Gronberg H. The natural history of prostate
cancer. In: Kaisary AV, Murphy GP, Denis L, Griffiths K, eds. Text-
book of Prostate Cancer. Pathology, Diagnosis and Treatment. London:
Martin Dunitz, 1999:1–10.
2. Siegal J, Brawer MK. Prostate-specific antigen. In: Kaisary AV, Murphy
GP, Denis L, Griffiths K, eds. Textbook of Prostate Cancer. Pathology, Di-
agnosis and Treatment. London: Martin Dunitz, 1999:121–2,134–5.
3. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-
specific antigen in serum as a screening test for prostate cancer.
N Engl J Med 1991;324:1156–61.
4. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a
decade of discovery – what we have learned and where we are going.
J Urol 1999;162:293–306.
5. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a
serum marker for adenocarcinoma of the prostate. N Engl J Med
1987;317:909–16.
6. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer
detection in a clinical urological practice by ultrasonography, dig-
ital rectal examination and prostate specific antigen. J Urol 1990;
143:1146–52.
7. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis
and treatment of adenocarcinoma of the prostate. I. Untreated
patients. J Urol 1989;141:1070–5.
8. Ercole CJ, Lange PH, Mathisen M, et al. Prostatic specific antigen
and prostatic acid phosphatase in the monitoring and staging of
patients with prostatic cancer. J Urol 1987;138:1181–4.
9. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in
the preoperative and postoperative evaluation of localized prostatic
cancer treated with radical prostatectomy. J Urol 1988;139:766–72.
10. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific
antigen, clinical stage and Gleason score to predict pathological
stage in men with localized prostate cancer. J Urol 1993;150:110–4.
11. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in
the staging of localized prostate cancer: influence of tumor
differentiation, tumor volume and benign hyperplasia. J Urol 1990;
143:747–52.
12. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival
in prostate cancer. A prospective, population-based study in Sweden.
JAMA 1997;277:467–71.
